Company / Cash & Equivalents
Vera Therapeutics, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$354.7M
FY2025
5-year range
$43.5M / $354.7M
FY2021-FY2025
Trend
+282.9%
vs FY2024
Sector context
#56 of 207
Health Care
What the data says
Cash & Equivalents changed +283% YoY in FY2025, a notable deviation from the 5-year average annual change of +79%.
Based on SEC 10-K filings.
$355M in FY2025 with a 5-year CAGR of +45.9%.
Improved from $46M to $355M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +101.3%
- 5-Year CAGR
- +45.9%
- 10-Year CAGR
- -
Sector benchmark
#56 of 207 in Health CareTop 27% of 207This company $354.7M Sector average $669.5M
▼
-47.0% below sector average
Key checks
Key Insights
- Vera Therapeutics, Inc.'s cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +45.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 282.9% year-over-year.
- Ranks #56 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $354.7M | +282.9% |
| FY2024 | $92.6M | +102.8% |
| FY2023 | $45.7M | +5.1% |
| FY2022 | $43.5M | -45.5% |
| FY2021 | $79.7M | +48.5% |
| FY2020 | $53.7M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026